(Q35619287)

English

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

scientific article published on 21 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

author name string

Melissa Chrispijn

1

1 reference

Europe PubMed Central

9 August 2017

Joost P H Drenth

2

1 reference

Europe PubMed Central

9 August 2017

publication date

21 November 2011

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

12

1 reference

Europe PubMed Central

9 August 2017

246

1 reference

Europe PubMed Central

9 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

21 November 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1745-6215-12-246

0 references

Systematic review: the pathophysiology and management of polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Medical and surgical treatment options for polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Autosomal dominant polycystic kidney disease: the last 3 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Sirolimus reduces polycystic liver volume in ADPKD patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Evaluation of a gastrointestinal symptoms questionnaire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240834

12 July 2018

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Somatostatin analogues reduce liver volume in polycystic liver disease

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Effect of octreotide on polycystic liver volume

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Everolimus in patients with autosomal dominant polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-12-246

21 January 2018

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22104015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/22104015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1745-6215-12-246

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35619287&oldid=1801493943"